Regenxbio has a competitive advantage in the market with its proprietary NAV technology platform, based on AAV vectors, that is highly effective, efficient, and scalable. The recent Phase II trial on ...

The global lentiviral vector CDMO market is projected to grow at a CAGR of 8% over the next five years. This growth is driven by rising demand for gene and cell therapies, an expanding pipeline of ...

Demand for lentiviral vectors will continue to outstrip supply until the industry has access to more efficient, purpose-built manufacturing and bioprocessing technologies. The warning comes from ...

A study on vector database and AI integration identifies unstable indexing, weak cross-modal fusion, and rigid resource ...

The science of gene therapy is enjoying a renaissance after ups and downs over the past 25 years. The heart of this field still largely relies on viral vector gene transfer systems that have evolved ...